You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved polihexanide (Akantior) to treat acanthamoeba keratitis. Acanthamoeba keratitis is an infection of the cornea, the clear ...

CATANIA, Italy, March 18, 2025 /PRNewswire/ -- SIFI, a leading international pharmaceutical company specializing in ophthalmology, is pleased to announce a scientific collaboration with the University ...

CATANIA, Italy, Sept. 30, 2024 /PRNewswire/ -- SIFI, a leading international ophthalmic company, announced that is has received a Notice of Allowance from the European Patent Office ("EPO") for ...

AKANTIOR (polihexanide) is the first and only medicinal product for the treatment of acanthamoeba keratitis – a rare, severe eye infection that often results in blindness and eye loss The marketing ...

AKANTIOR® (polihexanide) is the first and only approved drug for the treatment of acanthamoeba keratitis AK is an ultra-rare, severe, progressive and sight threatening corneal infection characterized ...

ACI SANT'ANTONIO, Italy, July 22, 2024 /PRNewswire/ -- SIFI, a leading international ophthalmic company headquartered in Italy, is pleased to announce that the Committee for Orphan Medicinal Products ...

CHMP opinion paves the way for Marketing Authorisation approval by the European Commission, currently anticipated in early August 2024. When approved, AKANTIOR will be the first licensed medicinal ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has backed approval for Akantior (polihexanide), a potential first medicine to treat acanthamoeba keratitis.